Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.

Fairly heart-breakingly for many people suffering from PTSD and other disorders, the US Food & Drug Agency has turned down Lykos Therapeutics new drug application for MDMA.

We offer directions for future research in minimising the risk of false and potentially harmful beliefs arising from psychedelics. Ultimately, knowing how psychedelics may facilitate false insights and beliefs is crucial if we are to optimally leverage their therapeutic potential.

Collectively, these results highlight dose, context, and serotonin receptors as crucial factors in psilocybin’s ability to facilitate fear extinction. The study provides preclinical evidence to support investigating psilocybin as a pharmacological adjunct for extinction-based therapy for PTSD.

A global survey of 68 researchers and clinicians underscores the necessity for standardized training, equitable access, and streamlined national approval processes for MDMA therapy, highlighting potential clinical benefits and challenges.

The US FDA is due to rule on licensing for MDMA next week. There are a plethora of articles about this forthcoming decision.

You can smoke changa, drink ayahuasca, or free-base or vaporizer DMT to have a DMT experience. But what are the pros and cons of each? 

The current study demonstrates across three cognitive domains, that acute responses to low doses of LSD depend on the baseline state and provides some support for LSD induced neuroadaptations that sustain beyond treatment.

Personality trait neuroticism decreased (P < 0.0001) and trait extraversion increased (P < 0.01) compared with study inclusion. Individuals attributed positive long-term effects to the psychedelic experience.  Conclusions Patients reported sustained long-term effects of LSD-assisted therapy for anxiety.

This study enhances our understanding of the LSD effect on the architecture and neural behavior of pain in healthy subjects and provides great promise for future research in the field of cognitive science and pharmacology.

As of 2024, some psychedelics have been given a legal or decriminalised foothold in: parts of Central Africa (Equatorial Guinea, Cameroon and Republic of the Congo), South Africa, Australia, the Bahamas, Brazil, the British Virgin Islands, Canada, the Czech Republic, Costa Rica, Israel, Jamaica, Mexico, Nepal, the Netherlands, Panama, Peru, Portugal, Samoa, Spain, Switzerland and the United States. 

In the long shadow of federal prohibition, a market for psychedelic shroom products is flourishing—and it’s rife with counterfeits and adulterants.

Psilocybin caused persistent decrease in functional connectivity between the anterior hippocampus and default mode network, lasting for weeks. Persistent reduction of hippocampal-default mode network connectivity may represent a neuroanatomical and mechanistic correlate of the proplasticity and therapeutic effects of psychedelics.

In this warm, informative podcast, our very own Dr Duncan Still is interviewed by Prof David Nutt of DrugScience (and many other ventures). Duncan talks about his own journey into medicine and particularly his passion for teaching more integrative approaches to health & healing.

Participants who reported lifetime co-use of cannabis and psychedelics (N = 63) were asked open-ended questions about their most recent simultaneous co-use experience.

PAP offers a promising avenue for a deeper understanding and therapeutic resolution of traumatic dissociation, which could fundamentally improve the treatment paradigm for many trauma-related disorders.

In this essay, we aim to explore the benefits and risks of integration groups, and offer a preliminary set of guidelines to physicians, researchers and individuals to help assess and evaluate these groups

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing.

This newsy article links to 7 recent psilocybin studies on alcohol use disorder, anorexia, long Covid, learning, brain connectivity, auditory perception and cluster headaches.

Searches for microdosing in the US remained stable until 2014, then increased annually thereafter, with a cumulative increase by a factor of 13.4 from 2015 to 2023 (7.9 per 10 million to 105.6 per 10 million searches, respectively). In 2023, there were 3.0 million microdosing searches in the US.